{"id":56648,"date":"2026-02-09T20:07:11","date_gmt":"2026-02-09T12:07:11","guid":{"rendered":"https:\/\/flcube.com\/?p=56648"},"modified":"2026-02-09T20:07:13","modified_gmt":"2026-02-09T12:07:13","slug":"guangdong-unveils-expanded-2025-greater-bay-area-access-list-for-115-hong-kong-and-macao-drugs-and-devices","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=56648","title":{"rendered":"Guangdong Unveils Expanded 2025 Greater Bay Area Access List for 115 Hong Kong and Macao Drugs and Devices"},"content":{"rendered":"\n

The Medical Products Administration of Guangdong Province (GDMPA)<\/strong> and Health Commission of Guangdong Province (GDHC)<\/strong> have released the “List of Urgently Needed Drugs and Medical Devices Imported from Hong Kong and Macao for Clinical Use in the Nine Mainland Cities of the Guangdong\u2011Hong Kong\u2011Macao Greater Bay Area (2025 Edition)”<\/strong>, expanding access to 115 products<\/strong>\u2014including 45 drugs and 70 medical devices<\/strong>\u2014across the mainland GBA cities.<\/p>\n\n\n\n

Policy Milestone<\/h2>\n\n\n\n
Item<\/th>Detail<\/th><\/tr><\/thead>
Issuing Authorities<\/strong><\/td>GDMPA + GDHC (Guangdong Province)<\/td><\/tr>
Policy Scope<\/strong><\/td>Nine mainland Greater Bay Area cities<\/td><\/tr>
Total Products<\/strong><\/td>115 (45 drugs + 70 medical devices)<\/td><\/tr>
Selection Model<\/strong><\/td>Pioneering “active leadership” mechanism (vs. passive acceptance)<\/td><\/tr>
Leading Varieties<\/strong><\/td>16 flagship products including orphan drugs and high\u2011end surgical equipment<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Selection Mechanism Innovation<\/h2>\n\n\n\n

The 2025 edition introduces a four\u2011channel sourcing model<\/strong> to identify urgently needed varieties:<\/p>\n\n\n\n

Channel<\/th>Description<\/th>Contribution<\/th><\/tr><\/thead>
National Urgently Needed List<\/strong><\/td>Products already designated as clinically urgent nationally and available in Hong Kong\/Macau<\/td>Regulatory alignment<\/td><\/tr>
Pre\u2011Review Database<\/strong><\/td>Varieties previously collected in GDMPA\u2019s screening database<\/td>Historical pipeline<\/td><\/tr>
Clinical Expert Recommendations<\/strong><\/td>Frontline physician and hospital pharmacist nominations<\/td>Unmet need validation<\/td><\/tr>
Enterprise Proposals<\/strong><\/td>Manufacturer and distributor submissions<\/td>Commercial supply\u2011side input<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Process:<\/strong> 129 candidate varieties \u2192 Two\u2011round GDMPA Evaluation and Inspection Center review \u2192 Expert panel assessment (clinical medicine, pharmacy, adverse reactions) \u2192 16 leading varieties finalized<\/strong><\/p>\n\n\n\n

Leading Varieties Profile<\/h2>\n\n\n\n
Category<\/th>Examples<\/th>Strategic Value<\/th><\/tr><\/thead>
Orphan Drugs<\/strong><\/td>Short bowel syndrome therapies, congenital thrombotic thrombocytopenic purpura treatments<\/td>Addresses rare disease gaps with limited domestic alternatives<\/td><\/tr>
Surgical Robotics<\/strong><\/td>Advanced robotic surgical systems<\/td>Accelerates minimally invasive surgery adoption in tier\u20111 GBA hospitals<\/td><\/tr>
Digestive Imaging<\/strong><\/td>Functional intraluminal imaging systems<\/td>Enhances endoscopic diagnostic precision for gastrointestinal diseases<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Market Impact & Regulatory Significance<\/h2>\n\n\n\n